Early Addition of Evolocumab to Statin Treatment in Patients with Acute Coronary Syndrome and Multivessel Disease Undergoing Percutaneous Coronary Intervention

Figures

• 

  Fig. 1.. Low-density lipoprotein cholesterol changes from baseline to 18 months in propensity-matched patients. LDL-C, low-density lipoprotein cholesterol.

• 

  Fig. 2.. Other lipid measurements in propensity-matched patients. HDL-C, high-density lipoprotein cholesterol; Non-HDL-C, Non-high-density lipoprotein cholesterol.

• 

  Fig. 3.. Time-to-event curves for the primary efficacy endpoint (A) and the principal secondary efficacy endpoint (B) in patients with acute coronary syndrome and multivessel disease undergoing percutaneous coronary intervention.

• 

  Fig. 4.. Subgroup analyses for the primary efficacy endpoint at 18 months. STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; LDL-C, low-density lipoprotein cholesterol; hs-CRP, hypersensitive C-reactive protein; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.